BGLC NASDAQ
BioNexus Gene Lab Corp.
1W: -12.2%
1M: -17.0%
3M: -41.9%
YTD: -69.0%
1Y: -77.7%
3Y: -84.9%
$1.27
+0.07 (+5.83%)
Weekly Expected Move ±9.4%
$1
$1
$1
$1
$1
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Cash Flow Trends
Operating Cash Flow
-$2M
-22.6% ▼
Capital Expenditures
$227K
-51.9% ▼
5Y CAGR: +77.7%
Free Cash Flow
-$2M
-24.8% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$2M
-168.0% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $1M | $752K | -$356K | -$3M | -$2M |
| Depreciation & Amort. | $102K | $108K | $105K | $108K | $153K |
| Stock-Based Comp. | $0 | $0 | $0 | $0 | $0 |
| Change in Working Capital | $102K | -$862K | $833K | $118K | $115K |
| Other Non-Cash Items | -$745K | $12K | -$31K | $642K | -$904K |
| Operating Cash Flow | $553K | $9K | $552K | -$2M | -$2M |
| — Investing Activities — | |||||
| Capital Expenditures | -$422K | -$3K | -$54K | -$149K | -$227K |
| Acquisitions (Net) | $346K | $0 | $0 | $0 | $0 |
| Investment Purchases | -$109K | -$516K | -$512K | -$321K | -$572K |
| Investment Sales | $30K | $6K | $0 | $26K | $1M |
| Other Investing | $1M | $22K | $115K | -$1M | $148K |
| Investing Cash Flow | $1M | -$491K | -$450K | -$2M | $418K |
| — Financing Activities — | |||||
| Net Debt Issuance | -$5K | -$26K | -$34K | $0 | $0 |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $0 | -$2K | -$8K | $525K | $145K |
| Financing Cash Flow | -$5K | -$28K | $108K | $6M | $145K |
| Net Change in Cash | $2M | -$664K | -$5K | $4M | -$2M |
| Cash End of Period | $3M | $2M | $2M | $6M | $3M |
| Free Cash Flow | $131K | $6K | $498K | -$2M | -$2M |